TY - JOUR
T1 - Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes
AU - Bhagwat, Priya
AU - Ofotokun, Ighovwerha
AU - McComsey, Grace A.
AU - Brown, Todd T.
AU - Moser, Carlee
AU - Sugar, Catherine A.
AU - Currier, Judith S.
N1 - Funding Information:
GAM has served as a scientific advisor for Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Pfizer, ICON and Gilead Sciences, and has received research grants from Bristol-Myers Squibb, GlaxoSmithKline and Gilead Sciences. TTB has served as a consultant to Gilead Sciences, Merck, AbbVie, EMD-Serono and Theratech-nologies, and his research is supported in part by NIH/ NIAID K24AI120834. The remaining authors declare no competing interests.
Funding Information:
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to acknowledge the sites that participated in ACTG A5260s. Please refer to the A5260s Acknowledgement Appendix for site specific grant numbers and acknowledgements (see Additional file 2). An earlier version of this manuscript was presented as a poster at the Conference on Retroviruses and Opportunistic Infections (CROI), 22–25 February 2016 in Boston, MA, USA. Poster number 704.
Publisher Copyright:
© 2017 International Medical Press.
PY - 2017
Y1 - 2017
N2 - Background: We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). Methods: Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. ART-naive HIV-infected participants were randomized to one of three contemporary ART regimens. Changes in abdominal CT-measured VAT and total adipose tissue (TAT) and DXA-measured trunk fat were tested for association with WC changes (by Pearson correlation) and categories of self-reported abdominal size changes (by ANOVA) between entry and week 96. Linear models compared WC and self-reported changes. Results: The study population (n=328) was predominantly male (90%) and White non-Hispanic (44%) with a baseline median age of 36 years and body mass index of 25 kg/m2. At week 96, median WC change was +2.8 cm. Of those reporting at week 96, 53% indicated ‘no change/lost’, 39% ‘gained some/somewhat larger’ and 8% ‘gained a lot/much larger’ as their self-reported changes. Trunk fat, VAT and TAT changes differed across self-reported groups (ANOVA P<0.0001 for all), and the group ordering was as expected. WC changes were strongly correlated with CT and DXA changes (trunk fat: r=0.72, p<0.0001; VAT: r=0.52, p<0.0001; TAT: r=0.62, p<0.0001). While WC changes explained a greater proportion of VAT, TAT and trunk fat variation, self-reported changes remained a significant predictor after controlling for WC (p<0.05). Conclusions: WC and self-reported abdominal changes each correlated directly with imaging-derived abdominal fat measures, and can be used as reliable, affordable tools for central adiposity assessment.
AB - Background: We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). Methods: Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. ART-naive HIV-infected participants were randomized to one of three contemporary ART regimens. Changes in abdominal CT-measured VAT and total adipose tissue (TAT) and DXA-measured trunk fat were tested for association with WC changes (by Pearson correlation) and categories of self-reported abdominal size changes (by ANOVA) between entry and week 96. Linear models compared WC and self-reported changes. Results: The study population (n=328) was predominantly male (90%) and White non-Hispanic (44%) with a baseline median age of 36 years and body mass index of 25 kg/m2. At week 96, median WC change was +2.8 cm. Of those reporting at week 96, 53% indicated ‘no change/lost’, 39% ‘gained some/somewhat larger’ and 8% ‘gained a lot/much larger’ as their self-reported changes. Trunk fat, VAT and TAT changes differed across self-reported groups (ANOVA P<0.0001 for all), and the group ordering was as expected. WC changes were strongly correlated with CT and DXA changes (trunk fat: r=0.72, p<0.0001; VAT: r=0.52, p<0.0001; TAT: r=0.62, p<0.0001). While WC changes explained a greater proportion of VAT, TAT and trunk fat variation, self-reported changes remained a significant predictor after controlling for WC (p<0.05). Conclusions: WC and self-reported abdominal changes each correlated directly with imaging-derived abdominal fat measures, and can be used as reliable, affordable tools for central adiposity assessment.
UR - http://www.scopus.com/inward/record.url?scp=85035150194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035150194&partnerID=8YFLogxK
U2 - 10.3851/IMP3148
DO - 10.3851/IMP3148
M3 - Article
C2 - 28248190
AN - SCOPUS:85035150194
SN - 1359-6535
VL - 22
SP - 577
EP - 586
JO - Antiviral therapy
JF - Antiviral therapy
IS - 7
ER -